Sleep apnea-hypopnea syndrome (SAHS) is a respiratory disorder characterized by cessation of breathing during sleep, resulting in daytime somnolence and various comorbidities. SAHS encompasses obstructive sleep apnea (OSA), caused by upper airway obstruction, and central sleep apnea (CSA), resulting from lack of brainstem signaling for respiration. Continuous positive airway pressure (CPAP) therapy is the gold standard treatment for SAHS, reducing apnea and hypopnea episodes by providing continuous airflow. CPAP enhances sleep quality and improves overall health by reducing the risk of comorbidities such as hypertension, type 2 diabetes mellitus, cardiovascular disease and stroke. CPAP nonadherence leads to health deterioration and occurs due to mask discomfort, unsupportive partners, upper respiratory dryness, and claustrophobia. Technological advancements such as auto-titrating positive airway pressure (APAP) systems, smart fit mask interface systems, and telemonitoring devices offer patients greater comfort and enhance adherence. Future research should focus on new technological developments, such as artificial intelligence, which may detect treatment failure and alert providers to intervene accordingly.
24 February 2026 in Journal of Stroke and Cerebrovascular Diseases
Patients with metabolic syndrome (MetS) are at increased risk of cerebrovascular disease. Given the limited data available, this study aims to explore contemporary trends in cerebrovascular disease-related mortality among patients aged 25 years and older in the United States (U.S.) with underlying MetS. We analyzed death data using the CDC WONDER database, extracting age-adjusted mortality rates (AAMR) per 100,000 population between 2000 and 2019. Using the ICD-10 codes, we identified fatalities where cerebrovascular disease was the underlying cause, while MetS was the contributing cause of death. We evaluated the trends by year, sex, race, census region, and metropolitan status. Joinpoint regression was used to calculate the annual percent change (APC) in AAMR with 95% confidence intervals. From 2000 to 2019, a total of 855,391 deaths occurred with an overall AAMR of 19.81. The overall AAMR decreased from 24.80 in 2000 to 16.92 in 2019. Women had a slightly higher AAMR (19.66) than men (19.32). Black or African American individuals had the highest AAMR (33.20). Significant geographical variations were observed, with the West (23.64) and Mississippi (27.74) having the highest AAMR as compared with other regions. Non-metropolitan areas had a higher AAMR (21.48) than metropolitan areas (19.46). Temporal analysis revealed that the mortality improvement, as measured by the annual percent change (APC) noted earlier in the study period, plateaued between 2014 and 2019. Notable sociodemographic disparities were also observed. These findings help identify vulnerable groups based on sociodemographic and geographic characteristics, guiding the development of targeted preventive interventions.
May-Thurner Syndrome (MTS) is caused by left common iliac vein compression, resulting in deep vein thrombosis (DVT). MTS is usually asymptomatic until DVT occurs. Our case features a 37-year-old woman who presented with swelling and pain in her left leg after recent travel and oral contraceptive use. Venous duplex ultrasound confirmed DVT and CT angiogram excluded pulmonary embolism. She received Heparin anticoagulation and underwent mechanical thrombectomy and stenting. Her symptoms improved within two days, and she was discharged on Apixaban and Plavix. This case involves a unique patient presentation of MTS, involving young woman with unexplained left-sided DVT, a scenario typically seen in older patients with clotting disorders.
19 September 2026 in European Heart Journal - Imaging Methods and Practice
Left ventricular thrombus (LVT) is a significant complication of myocardial infarction, associated with increased morbidity and mortality because of the risk of systemic embolization and stroke. Early detection of LVT is therefore important for the timely initiation of anticoagulation therapy. This systematic review and meta-analysis compared the diagnostic accuracy of cardiac magnetic resonance (CMR) with transthoracic echocardiography (TTE) for the detection of LVT. Following PRISMA guidelines, PubMed, Cochrane, CNKI, Scopus, LILACS, Web of Science, Google Scholar, EMBASE, and CINAHL were searched. Random-effects meta-analyses were performed in R (v3.4.3), with pooled proportions or area under the curve (AUC) values reported alongside 95% confidence intervals, and heterogeneity assessed using the I² statistic. Eighteen studies involving 3478 participants met the inclusion criteria. Most studies contributed to the primary analysis of TTE performance using CMR as the reference standard, while only five studies allowed direct head-to-head comparison using an independent reference standard. In the head-to-head analysis, CMR demonstrated higher sensitivity (70.5%, 95% CI: 0.554-0.822) and specificity (99.2%, 95% CI: 0.983-0.997) for detecting LVT compared with TTE, which showed a sensitivity of 31.8% (95% CI: 0.252-0.391) and specificity of 96.3% (95% CI: 0.929-0.981). The AUC for CMR was 0.985 compared with 0.59 for TTE. Heterogeneity was significant for TTE (I² = 75.8%) but low for CMR (I² = 0.0%). Funnel-plot assessment suggested a low likelihood of publication bias. These findings suggest that CMR may provide a diagnostic advantage over TTE for LVT detection, particularly in high-risk patients or when TTE findings are negative or inconclusive. However, this apparent advantage should be interpreted cautiously because most included studies used CMR, particularly late gadolinium enhancement CMR, as the reference standard rather than an independent imaging modality or pathological confirmation, and many studies were historical and used heterogeneous or non-optimized echocardiographic protocols. Further contemporary studies using independent validation standards are needed. Systematic Review Registration: PROSPERO CRD 42024558739